Clenoliximab
Alternative Names: Anti-CD4 monoclonal antibody IDEC 151; IDEC 151; Lenoliximab; PRIMATIZED anti-CD4 antibody IDEC 151; SB 217969Latest Information Update: 10 Aug 2006
At a glance
- Originator Biogen Idec
- Class Monoclonal antibodies
- Mechanism of Action CD4 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 10 Aug 2006 Discontinued - Phase-II for Rheumatoid arthritis in United Kingdom (unspecified route)
- 10 Aug 2006 Discontinued - Phase-II for Rheumatoid arthritis in USA (unspecified route)
- 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec